Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
SMC021 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| SMC021 | DRUG | - |
Inclusion Criteria: * Healthy postmenopausal female subjects, 40 to 70 years of age, and in good health as determined by past medical history, physical examination, vital signs, electrocardiogram, and laboratory tests at screening. * At Screening, and Baseline, vital signs (systolic and diastolic b...
SMC021 is an investigational small molecule developed by Novartis AG for use in healthy postmenopausal women. It is a calcitonin receptor (CALCR) agonist studied in the endocrine therapeutic area. SMC021 has been evaluated in a Phase 2 clinical trial and is not described as approved; it remains an investigational agent in clinical development.
SMC021 targets CALCR, the calcitonin receptor. It acts as an agonist at this receptor. The calcitonin receptor is a G protein-coupled receptor involved in calcium regulation, and SMC021 was studied as a small molecule agonist of it in healthy postmenopausal women.
SMC021 is developed by Novartis AG, which trades under the ticker NVS. Novartis is the sponsor associated with the clinical development of this calcitonin receptor agonist small molecule.
SMC021 is in Phase 2 development. One Phase 2 trial has been completed, and no active trials are ongoing. The drug is investigational and has not been described as approved by the FDA.
SMC021 has been studied in one completed Phase 2 trial, NCT00421590, titled "Drug Interaction of SMC021 With Concomitant Antacid (Calcium Carbonate/Magnesium Hydroxide)." The trial enrolled 38 participants, was randomized and double blind, and was conducted in Denmark in healthy postmenopausal women aged 40 years and older.
SMC021 has been studied in healthy postmenopausal women within the endocrine therapeutic area. Its only listed clinical trial evaluated a drug interaction with a concomitant antacid, calcium carbonate and magnesium hydroxide. The drug remains investigational, and no approved indication has been described for it.